Scientific deep-dive

GLP-1 Drugs and Eating Disorders: Two Questions, One Studied

Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

Two questions sit under this heading and only one of them has been studied. The researched question is whether these drugs treat binge eating disorder: a 2025 meta-analysis found five studies covering 182 participants, with greater weight loss of 3.81 kg.[1] The unstudied question is what happens when a powerful appetite suppressant reaches someone with a restrictive eating disorder, a group deliberately excluded from every trial. If you are asking the second question about yourself, the evidence below is not the thing you need.

If your relationship with eating is the reason you are reading this, the National Alliance for Eating Disorders runs a free helpline staffed by clinicians: +1 (866) 662-1235. Eating disorders carry some of the highest mortality of any psychiatric illness, and they are treatable. That is a better first call than any weight-loss prescriber.

What has been measured

Of all eating disorders, binge eating disorder is the most common, and it is also the one where a drug affecting appetite and reward signaling has an obvious rationale. A 2025 systematic review and meta-analysis searched four databases and found five eligible studies, together enrolling 182 people.[1] Pooled, GLP-1 treatment produced 3.81 kg more weight loss than comparators.

The headline result is about weight, but the condition is defined by episodes of eating and loss of control, not by body size. A treatment can move the scale in someone with binge eating disorder without touching the binges, and weight is the easier thing to measure.

Five studies and 182 people is a small literature. The reviewers say so themselves and call for comprehensive trials, particularly for eating disorders other than binge eating disorder and for long-term effects.[1] Anyone describing these drugs as a treatment for eating disorders is well ahead of that.

The psychiatric picture is mixed

A 2026 systematic review looked at semaglutide specifically through a psychiatric lens, screening 342 papers down to 37 covering cohorts, pharmacovigilance, open-label studies and randomized trials.[2] Its summary is that semaglutide appears effective and well tolerated across several psychiatric populations, with promise in binge eating disorder, including effects on cognitive symptoms as well as weight.

The same summary notes that these drugs have been linked to depressive symptoms and suicidal ideation, alongside possible antidepressant effects, and describes the evidence for all of it as preliminary.[2] (Bupropion, the antidepressant in Contrave, is contraindicated in bulimia and anorexia; see antidepressants and a GLP-1.)

Both findings sit in one review because the field is still immature. Our suicidality article covers the specific question of self-harm, where the larger evidence base points reassuringly and the labels changed accordingly in February 2026.

The question nobody is running trials on

Trials of appetite-suppressing drugs exclude people with active restrictive eating disorders, for obvious ethical reasons. That exclusion means the trial literature is silent on a situation that is now common: someone with anorexia nervosa, bulimia, or subclinical restriction obtaining a drug whose entire purpose is to make eating feel unnecessary.

Trials of these drugs exclude people with active restrictive eating disorders, so the evidence is silent on them.

Two features of the current market make this worse. Telehealth prescribing is fast and largely questionnaire-based, and compounded sellers operate with less screening still (our pharmacy verification guide covers what a legitimate intake looks like). A BMI threshold is not an eating disorder screen, and someone with a restrictive disorder at a high body weight will pass one.

  • Rapid weight loss can mask a disorder rather than reveal it, because the loss is attributed to the drug and treated as success.
  • Losing the physical cue of hunger removes a signal that recovery-oriented treatment works to restore.
  • The drugs are effective, which means an eating disorder can progress while every number on the chart looks like a good outcome.

What to do with this

If you have had an eating disorder in the past and are thinking about one of these drugs, that history belongs in the first conversation, not a later one. It is not automatically disqualifying, since binge eating disorder and obesity overlap heavily and the modest evidence points the right way. But it changes who should be involved and what gets monitored.

If someone you know has lost weight rapidly on one of these and their eating has become rigid, secretive or frightening to them, name it out loud. The drug working is not evidence that nothing is wrong.

Frequently Asked Questions

The evidence is early and small. A 2025 meta-analysis found five studies covering 182 participants, with 3.81 kg more weight loss than comparators. The headline outcome is weight, not binge frequency, and the reviewers call for comprehensive trials before drawing conclusions.
That is a clinical judgment, not a general answer, and it belongs in the first conversation rather than a later one. A history is not automatically disqualifying (binge eating disorder and obesity overlap heavily), but it changes who should be monitoring and what they should watch.
Trials of appetite-suppressing drugs exclude people with active restrictive eating disorders for ethical reasons. That means the literature is silent on a situation that is now common, and silence is not reassurance.
Nobody has studied it directly, and there are clear mechanisms for concern: rapid weight loss gets attributed to the drug rather than examined, the physical cue of hunger that recovery works to restore is removed, and the illness can progress while every measurement looks like success.
No. A BMI threshold is a weight criterion, not a psychiatric screen, and someone with a restrictive disorder at a higher body weight will pass one. Questionnaire-based telehealth intake widens that gap.

References

  1. 1.Radkhah H, Rahimipour Anaraki S, Parhizkar R, et al. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis Eating and Weight Disorders. 2025. PMID: 39891848.
  2. 2.Carminati M, Tondello M, Concina A, et al. Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks International Clinical Psychopharmacology. 2026. PMID: 40577093.

GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk

A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.

6 min read

GLP-1 Drugs and Headache: A Side Effect, and a Treatment

Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.

7 min read

Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist

The most detailed published evidence that GLP-1 drugs cause dry mouth is three case reports, alongside an adverse-event reporting signal for semaglutide. Nobody has measured how often it happens, but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.

5 min read

GLP-1 Drugs After 65: Strength, Not Just Weight

Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.

7 min read

Phentermine and a GLP-1 Together: What the Labels and Trials Show

Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.

10 min read

Ozempic and the Vagina: Dryness, Odor and Yeast Infections

No GLP-1 label lists a vaginal side effect. Genital yeast infections belong to SGLT2 diabetes drugs such as Jardiance, and GLP-1 users had fewer of them in cohort studies. What FDA reports show, likely causes of dryness and odor, and when to see a clinician.

11 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

9.1

Collective

From $59/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →